相似文献
1
Is the immune hyporesponsiveness of uremic patients a protective factor for severe COVID-19 pneumonia?尿毒症患者的免疫低反应性是重症新型冠状病毒肺炎的保护因素吗？
Nefrologia (Engl Ed). 2021 Mar-Apr;41(2):223-224. doi: 10.1016/j.nefro.2020.05.002. Epub 2020 May 23.
2
[SARS-CoV-2 vaccines - what the nephrologist should know].[严重急性呼吸综合征冠状病毒2型疫苗——肾病学家应该知道的内容]
Dtsch Med Wochenschr. 2021 Apr;146(7):466-470. doi: 10.1055/a-1375-4471. Epub 2021 Mar 29.
3
Special Issue: Immune Dysfunction in Uremia.特刊：尿毒症中的免疫功能障碍。
Toxins (Basel). 2021 Jan 19;13(1):70. doi: 10.3390/toxins13010070.
4
Protein-Bound Uremic Toxins and Immunity.蛋白结合型尿毒症毒素与免疫
Methods Mol Biol. 2021;2325:215-227. doi: 10.1007/978-1-0716-1507-2_15.
5
Inflammation and premature aging in advanced chronic kidney disease.晚期慢性肾脏病中的炎症与早衰
Am J Physiol Renal Physiol. 2017 Oct 1;313(4):F938-F950. doi: 10.1152/ajprenal.00256.2017. Epub 2017 Jul 12.
6
Endothelial Damage, Inflammation and Immunity in Chronic Kidney Disease.慢性肾脏病中的内皮损伤、炎症与免疫
Toxins (Basel). 2020 Jun 1;12(6):361. doi: 10.3390/toxins12060361.
7
Chronic Kidney Disease-Associated Immune Dysfunctions: Impact of Protein-Bound Uremic Retention Solutes on Immune Cells.慢性肾脏病相关免疫功能紊乱：蛋白结合型尿毒症潴留溶质对免疫细胞的影响。
Toxins (Basel). 2020 May 6;12(5):300. doi: 10.3390/toxins12050300.
8
Monocytes in Uremia.尿毒症中的单核细胞。
Toxins (Basel). 2020 May 21;12(5):340. doi: 10.3390/toxins12050340.
9
Severe acute kidney injury associated with progression of chronic kidney disease after critical COVID-19.重症新型冠状病毒肺炎（COVID-19）后严重急性肾损伤与慢性肾脏病进展相关
Crit Care. 2021 Jan 25;25(1):37. doi: 10.1186/s13054-021-03461-4.
10
Uremic Stomatitis.尿毒症性口炎
N Engl J Med. 2020 Jun 25;382(26):2556. doi: 10.1056/NEJMicm1914867.
本文引用的文献
1
SARS-CoV-2 infection in patients on renal replacement therapy. Report of the COVID-19 Registry of the Spanish Society of Nephrology (SEN).接受肾脏替代治疗患者的新型冠状病毒2型感染。西班牙肾脏病学会（SEN）COVID-19登记报告。
Nefrologia (Engl Ed). 2020 May-Jun;40(3):272-278. doi: 10.1016/j.nefro.2020.04.002. Epub 2020 Apr 16.
2
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
3
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
4
Extracorporeal Blood Purification Therapies for Sepsis.脓毒症的体外血液净化疗法。
Blood Purif. 2019;47 Suppl 3:1-14. doi: 10.1159/000499520. Epub 2019 Apr 11.
5
Hemoadsorption by CytoSorb in septic patients: a case series.细胞吸附剂（CytoSorb）对脓毒症患者的血液吸附：病例系列
Crit Care. 2017 Mar 27;21(1):74. doi: 10.1186/s13054-017-1662-9.
6
Extracorporeal virus elimination for the treatment of severe Ebola virus disease--first experience with lectin affinity plasmapheresis.体外病毒清除治疗重症埃博拉病毒病——凝集素亲和血浆置换的首次经验
Blood Purif. 2014;38(3-4):286-91. doi: 10.1159/000375229. Epub 2015 Feb 11.
7
Evaluation of plasma exchange and continuous veno-venous hemofiltration for the treatment of severe avian influenza A (H7N9): a cohort study.血浆置换和持续静脉-静脉血液滤过治疗重症甲型H7N9禽流感的队列研究
Ther Apher Dial. 2015 Apr;19(2):178-84. doi: 10.1111/1744-9987.12240. Epub 2014 Nov 3.
8
Immune dysfunction in uremia—an update.尿毒症中的免疫功能障碍——最新进展。
Toxins (Basel). 2012 Oct 24;4(11):962-90. doi: 10.3390/toxins4110962.
9
Impaired cellular immune function in patients with end-stage renal failure.终末期肾衰竭患者的细胞免疫功能受损。
Nephrol Dial Transplant. 1999 Dec;14(12):2807-10. doi: 10.1093/ndt/14.12.2807.
Zotero 插件